KYTX

Dollar change -0.04
Percentage change -0.90	%

Peers: MRNA AMGN VRTX JNJ REGN GILD BMRN PFE BMY NVAX

| Held by: VTI IWM VXF SCHA IWO VTWO IWN IWC SBIO VTWG

Index	RUT	P/E	-	EPS (ttm)	-3.07	Insider Own	56.65%	Shs Outstand	43.17M	Perf Week	-2.86%
Market Cap	189.11M	Forward P/E	-	EPS next Y	-3.69	Insider Trans	0.00%	Shs Float	18.72M	Perf Month	-12.65%
Income	-110.66M	PEG	-	EPS next Q	-0.84	Inst Own	31.26%	Short Float	11.24%	Perf Quarter	-35.85%
Sales	0.00M	P/S	-	EPS this Y	96.32%	Inst Trans	-17.47%	Short Ratio	5.68	Perf Half Y	-53.62%
Book/sh	7.01	P/B	0.63	EPS next Y	-11.84%	ROA	-	Short Interest	2.10M	Perf Year	-
Cash/sh	7.52	P/C	0.59	EPS next 5Y	-	ROE	-	52W Range	3.92 - 35.06	Perf YTD	-85.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-35.94%	52W High	-87.39%	Beta	-
Dividend TTM	-	Quick Ratio	10.50	Sales past 5Y	-37.90%	Gross Margin	-	52W Low	12.76%	ATR (14)	0.51
Dividend Ex-Date	-	Current Ratio	10.50	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	43.29	Volatility	9.03% 11.25%
Employees	96	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.29	Target Price	24.50
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-122.75%	Payout	-	Rel Volume	0.82	Prev Close	4.46
Sales Surprise	-	EPS Surprise	1.76%	Sales Q/Q	-	Earnings	Nov 13 AMC	Avg Volume	370.15K	Price	4.42
SMA20	-7.66%	SMA50	-11.32%	SMA200	-60.98%	Trades		Volume	305,001	Change	-0.90%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-24	Initiated	UBS	Buy	$13
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$16
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
11:13AM	Loading…
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
04:05PM	Loading…
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Walker Karen Marie	Chief Technology Officer	Jun 06 '24	Option Exercise	4.42	9,636	42,591	9,636	Jun 10 06:56 PM
Jones Ryan Alexander	Chief Financial Officer	May 28 '24	Option Exercise	0.73	18,016	13,152	43,950	May 29 04:33 PM
Vida Ventures, LLC	10% Owner	Feb 12 '24	Buy	22.00	253,136	5,568,992	252,553	Feb 14 07:04 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	3,163,868	Feb 14 05:26 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
Northpond Ventures III GP, LLC	Former 10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	450,000	Feb 12 05:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Kyverna Therapeutics Inc

Upgrade your FINVIZ experience